alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 54 studies with an author at University of Turin (IT) (page 2 of 3) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 54 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Rheumatoid arthritis: Extra-articular manifestations and comorbidities

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Autoimmunity reviews 2021-02-17

Although synovitis is the pathological hallmark of rheumatoid arthritis (RA), many extra-articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic, inflammatory, and autoimmune features of RA. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature genetics 2026-09-14

Among the more than 90 identified genetic risk loci for late-onset Alzheimer's disease (AD) and related dementias, the apolipoprotein E (APOE) gene ɛ2/ɛ3/ɛ4 polymorphisms remain the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1-10 . 5 key findings →

Design: case-control Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo

✓ Peer-reviewed alzhub usefulness score 49 out of 100. EMBO molecular medicine 2018-01-01

Intronic GGGGCC repeat expansions in C9orf72 are the most common known cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are characterised by degeneration of cortical and motor neurons, respectively. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications

✓ Peer-reviewed alzhub usefulness score 47 out of 100. International journal of molecular sciences 2024-11-06

The identification of neuroinflammation as a critical factor in Alzheimer's disease (AD) has expanded the focus of research beyond amyloid-β and tau pathology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive changes and emotional heart rate variability dynamics in subjective cognitive decline: An exploratory longitudinal neuropsychophysiological study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Acta Psychologica 2026-01-23

Subjective cognitive decline (SCD) is increasingly recognised as a potential preclinical stage of Alzheimer's disease, yet the physiological mechanisms underlying its progression remain poorly understood. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Oxidized cholesterol as the driving force behind the development of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in aging neuroscience 2015-06-19

Alzheimer's disease (AD), the most common neurodegenerative disorder associated with dementia, is typified by the pathological accumulation of amyloid Aβ peptides and neurofibrillary tangles (NFT) within the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Blood-Based Biomarkers in Transforming Alzheimer’s Disease Research and Clinical Management: A Review

✓ Peer-reviewed alzhub usefulness score 44 out of 100. International Journal of Molecular Sciences 2025-09-03

Alzheimer's disease (AD) is a progressive neurodegenerative condition representing the most common cause of dementia and currently affects millions of people worldwide. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lung ultrasound (LUS) as a predictor of delirium in elderly patients with COVID-19 during hospitalization: A geriatric vulnerability-stress model

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Archives of Gerontology and Geriatrics Plus 2025-07-02

LUS and cognitive impairment are strong predictors of delirium in elderly COVID-19 patients. 3 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Neurological Sciences 2025-10-17

This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer's disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium in the emergency department: Incidence and risk factors in a Ligurian hospital

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Archives of Gerontology and Geriatrics Plus 2025-04-26

Delirium, a severe neuropsychiatric syndrome characterised by acute deficits in attention and self-awareness, is common among elderly inpatients, with incidence increasing with age and prolonged hospitalisation. 2 key findings →

Participants: 89 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rescue of protein dyshomeostasis in hippocampal astrocytes from an Alzheimer’s disease mouse model by stabilizing ER-mitochondrial interactions at a 20 nm distance

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s Research & Therapy 2025-07-04

Autophagic markers beclin 1, LC3II and p62, and lysosome-related marker cathepsin B, all upregulated in AD astrocytes, were significantly reduced, while autophagic flux was rescued, by stabilizing 20 nm-MERCS. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

UCH-L1 in Alzheimer’s Disease: A Crucial Player in Dementia-Associated Mechanisms

✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Molecular Sciences 2025-09-16

Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is a critical deubiquitinating enzyme that is highly expressed in the central nervous system, where it participates in protein degradation and turnover as part of the ubiquitin-proteasome system (UPS). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The perceptions of European geriatricians on the co-occurrence and links between dementia, delirium and frailty

✓ Peer-reviewed alzhub usefulness score 40 out of 100. European Geriatric Medicine 2025-03-15

Within the 440 included surveys, respondents particularly over-estimated frailty prevalence in older hospitalised patients, with two-thirds choosing between 41 and 80% prevalence, when the literature suggests only 23-46%, but paradoxically underestimated the frequency of frailty in people with delirium (more than three quarters of responses across 21-80%; literature suggests 71-93%). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Neurology Neurosurgery & Psychiatry 2021-02-09

Since its first description by Charcot, amyotrophic lateral sclerosis (ALS) has been classified as a single neurodegenerative disease involving motor neurons. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Assessing brain vascular impairment, white matter lesions and ApoE status as predictors of behavioral and psychological symptoms of dementia (BPSD) in a multicentre sample of patients with Alzheimer's disease: a multidisciplinary retrospective study

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Annali dell'Istituto superiore di sanita 2025-03-19

BPSD severity was independent from cognitive impairment, vascular impairment, white matter lesions and ApoE status. 3 key findings →

Design: cross-sectional Participants: 92 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed